The TREAT Asia HIV Observational Database: Baseline and retrospective data

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 2, 2005, Pages 174-179

  Zhou, Jialun ^a   Kumarasamy, N ^b   Ditangco, Rossana ^c   Kamarulzaman, Adeeba ^d   Lee, Christopher K C ^e   Li, Patrick C K ^f   Paton, Nicholas I ^g   Phanuphak, Praphan ^h   Pujari, Sanjay ⁱ   Vibhagool, Asda ^j   Wong, Wing Wai ^k   Zhang, Fujie ^l   Chuah, John ^m   Frost, Kevin R ⁿ   Cooper, David A ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^c RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e HOSPITAL KUALA LUMPUR   (Malaysia)

^f QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^g TAN TOCK SENG HOSPITAL   (Singapore)

^h THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

ⁱ HIV Project   (India)

^j MAHIDOL UNIVERSITY   (Thailand)

^k NATIONAL YANG MING UNIVERSITY   (Taiwan)

^l CAPITAL MEDICAL UNIVERSITY   (China)

^m Gold Coast Sexual Health Clinic   (Australia)

ⁿ Amer Foundation for AIDS Research   (United States)

more..

Author keywords

Antiretroviral treatment; Asia and the Pacific; HIV; Observational database

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ASIA; CLINICAL FEATURE; CLINICAL OBSERVATION; COHORT ANALYSIS; DATA BASE; DISEASE ACTIVITY; DISEASE COURSE; ETHNOLOGY; FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUAL INTERCOURSE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 19944433996     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000145351.96815.d5     Document Type: Article

References (15)

1. Kumarasamy N, Solomon S, Flanigan TP, et al. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis. 2003;36:79-85.
2. Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci. 2003;57:16-21.
3. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
4. Petoumenos K. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database. J Clin Virol. 2003;26:209-222.
5. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
6. Jensen-Fangel S, Pedersen C, Larsen CS, et al. Changing demographics in an HIV-infected population: results from an observational cohort study in Western Denmark. Scand J Infect Dis. 2001;33:765-770.
7. Easterbrook PJ, Farzadegan H, Hoover DR, et al. Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. AIDS. 1996;10:1147-1155.
8. Schellekens PT, Tersmette M, Roos MT, et al. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS. 1992;6:665-669.
9. Lyles CM, Margolick JB, Astemborski J, et al. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS. 1997;11:1255-1262.
10. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS. 2003;17:963-969.
11. Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 2002;7:21-30.
12. Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171-1180.
13. French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials. 2002;3:177-185.
14. EfaVIP Cohort Group. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr. 2004;35:343-350.
15. Galai N, Vlahor D, Margolick JB, et al. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:66-74.